Cellosaurus cell line KTOR2-RE (CVCL

Entry history
Cell line name	KTOR2-RE
Accession	CVCL_E6D9
Resource Identification Initiative	To cite this cell line use: KTOR2-RE (RRID:CVCL_E6D9)
Comments	Population: Japanese. Donor information: Established from the patient after relapse and acquired resistance to ALK inhibitors (PubMed=31900393). Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations	Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK; Note=E13A20 v1 fusion (PubMed=31900393). Mutation; HGNC; HGNC:427; ALK; Simple; p.Leu1196Met (c.3586C>A); ClinVar=VCV000376135; Zygosity=Unspecified (PubMed=31900393).
Disease	Lung non-small cell carcinoma (NCIt: C2926)
Species of origin	Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual	CVCL_E6D8 ! KTOR2
Sex of cell	Male
Age at sampling	76Y
Category	Cancer cell line
Publications	PubMed=31900393; DOI=10.1038/s41467-019-13771-5; PMCID=PMC6941996 Tsuji T., Ozasa H., Aoki W., Aburaya S., Yamamoto Funazo T., Furugaki K., Yoshimura Y., Yamazoe M., Ajimizu H., Yasuda Y., Nomizo T., Yoshida H., Sakamori Y., Wake H., Ueda M., Kim Y.H., Hirai T. YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nat. Commun. 11:74.1-74.16(2020)
Entry creation	10-Apr-2025
Last entry update	10-Apr-2025
Version number	1